H. Pylori Infection

2
Pipeline Programs
2
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Phathom Pharmaceuticals
Phathom PharmaceuticalsFLORHAM PARK, NJ
1 program
1
PYTEST® 14C-Urea Capsule Breath TestPhase 41 trial
Active Trials
NCT07224048Active Not RecruitingEst. Nov 2027
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-438Phase 35 trials
Active Trials
NCT03808493Completed48Est. Mar 2019
NCT03085836Completed33Est. Aug 2017
NCT01630746Completed19Est. Sep 2013
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Phathom PharmaceuticalsPYTEST® 14C-Urea Capsule Breath Test
TakedaTAK-438
TakedaTAK-438
TakedaTAK-438
TakedaTAK-438
TakedaTAK-438
TakedaTAK-438
TakedaTAK-438

Clinical Trials (8)

Total enrollment: 1,112 patients across 8 trials

NCT07224048Phathom PharmaceuticalsPYTEST® 14C-Urea Capsule Breath Test

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2

Start: Nov 2024Est. completion: Nov 2027
Phase 4Active Not Recruiting

A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis

Start: Jul 2012Est. completion: Sep 201319 patients
Phase 3Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy

Start: May 2012Est. completion: Aug 201327 patients
Phase 3Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Start: Apr 2012Est. completion: Sep 201330 patients
Phase 3Completed

Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

Start: Jan 2012Est. completion: Jun 2013650 patients
Phase 3Completed

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Start: Sep 2011Est. completion: Jul 2013305 patients
Phase 3Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Start: Jan 2019Est. completion: Mar 201948 patients
Phase 1Completed

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

Start: Apr 2017Est. completion: Aug 201733 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space